Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.39 |
| ▸ | IDO1 | P14902 | 4/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30267608 | 1.00 | NAMPT (0.41) | NAMPTGPR119IDO1BACE1USP30 | |
| SCHEMBL23930395 | 0.86 | FABP5 (0.40) | — | |
| SCHEMBL15297397 | 0.83 | USP30 (0.41) | NAMPTGPR119IDO1BACE1USP30 | |
| SCHEMBL25228434 | 0.83 | BACE1 (0.40) | NAMPTGPR119IDO1BACE1KDM4E | |
| SCHEMBL25276658 | 0.82 | IDO1 (0.41) | NAMPTGPR119IDO1BACE1USP30 | |
| SCHEMBL31688597 | 0.82 | NAMPT (0.42) | NAMPTIDO1BACE1USP30JAK2 | |
| SCHEMBL3580338 | 0.82 | GPR119 (0.44) | GPR119IDO1BACE1USP30JAK2 | |
| SCHEMBL25657529 | 0.80 | KMT2A (0.39) | — | |
| SCHEMBL25797253 | 0.80 | KMT2A (0.41) | — | |
| SCHEMBL15297396 | 0.79 | JAK2 (0.39) | NAMPTGPR119IDO1BACE1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323946-A1 | PROCESS FOR PREPARING A PHTHALAZINONE DERIVATIVE AND INTERMEDIATES THEREOF | IDIENCE CO., LTD. (KR) | 2021-10-21 | — | — | US | claimed |
| US-12060345-B2 | Process for preparing a phthalazinone derivative and intermediates thereof | IDIENCE CO., LTD. (KR) | 2024-08-13 | — | — | US | disclosed |
| US-11691964-B2 | Crystalline forms of phthalazinone compound | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-07-04 | — | — | US | disclosed |
| EP-4139297-A1 | CRYSTALLINE FORMS OF PHTHACAZ1NONF COMPOUND | Idience Co., Ltd. (KR) | 2023-03-01 | — | — | EP | disclosed |
| US-20220372020-A1 | CRYSTALLINE FORMS OF PHTHALAZINONE COMPOUND | IDIENCE CO., LTD. (KR) | 2022-11-24 | — | — | US | disclosed |
| US-11390608-B2 | Crystalline forms of phthalazinone compound | IDIENCE CO., LTD. (KR) | 2022-07-19 | — | — | US | disclosed |
| WO-2021214503-A1 | CRYSTALLINE FORMS OF PHTHACAZ1NONF COMPOUND | IDIENCE CO., LTD. (KR) | 2021-10-28 | — | — | WO | disclosed |
| US-20210323946-A1 | PROCESS FOR PREPARING A PHTHALAZINONE DERIVATIVE AND INTERMEDIATES THEREOF | IDIENCE CO., LTD. (KR) | 2021-10-21 | — | — | US | disclosed |
| US-20210323945-A1 | CRYSTALLINE FORMS OF PHTHALAZINONE COMPOUND | IDIENCE CO., LTD. (KR) | 2021-10-21 | — | — | US | disclosed |
| US-20210323946-A1 | PROCESS FOR PREPARING A PHTHALAZINONE DERIVATIVE AND INTERMEDIATES THEREOF | IDIENCE CO., LTD. (KR) | 2021-10-21 | — | — | US | disclosed |
| US-20170037316-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220372020-A1 | CRYSTALLINE FORMS OF PHTHALAZINONE COMPOUND | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC1, UACA | NAMPT 2227/4885GPR119 1083/4885IDO1 3418/4885 |
| US-20170037316-A1 | LIQUID-CRYSTALLINE MEDIUM | FES, NEFM, SOST | NAMPT 875/4885GPR119 2720/4885IDO1 1940/4885 |
| US-11390608-B2 | Crystalline forms of phthalazinone compound | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC1, UACA | NAMPT 2227/4885GPR119 1083/4885IDO1 3418/4885 |
| US-20210323945-A1 | CRYSTALLINE FORMS OF PHTHALAZINONE COMPOUND | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC1, UACA | NAMPT 2227/4885GPR119 1083/4885IDO1 3418/4885 |
| US-12060345-B2 | Process for preparing a phthalazinone derivative and intermediates thereof | AZI2, NISCH, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | NAMPT 1520/4885GPR119 2747/4885IDO1 2033/4885 |
| US-11691964-B2 | Crystalline forms of phthalazinone compound | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC1, UACA | NAMPT 2227/4885GPR119 1083/4885IDO1 3418/4885 |
| US-20210323946-A1 | PROCESS FOR PREPARING A PHTHALAZINONE DERIVATIVE AND INTERMEDIATES THEREOF | NISCH, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, DHPS | NAMPT 837/4885GPR119 2605/4885IDO1 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.